Table 3

HG-7-85-01 effect on apoptosis

Cell linePercentageHG-7-85-01, 0μMHG-7-85-01, 0.01μMHG-7-85-01, 0.1μMHG-7-85-01, 1μM
32D-BCR-ABL Viable 96.5 94 47.1 4.6 
 Apoptotic 3.3* 5.8* 52.3* 95.3* 
 Necrotic 0.2 0.2 0.6 0.1 
32D-BCR-ABL-T315I Viable 96.6 90.8 89.9 27.2 
 Apoptotic 3.4* 9* 9.8* 72.7* 
 Necrotic 0.1 0.3 
Ba/F3-KIT-T670I Viable 96.8 97.7 96.9 91.6 
 Apoptotic 3.2* 2.3* 3.1* 8.4* 
 Necrotic 
Ba/F3-PDGFRα-T674M Viable 92.2 91 34.7 13.2 
 Apoptotic 7.8* 9* 65.2* 86.8* 
 Necrotic 0.1 
Ba/F3-PDGFRα-T674I Viable 87.3 61.9 15.2 5.8 
 Apoptotic 12.8* 38.1* 84.7* 94.1* 
 Necrotic 0.1 0.2 
Cell linePercentageHG-7-85-01, 0μMHG-7-85-01, 0.01μMHG-7-85-01, 0.1μMHG-7-85-01, 1μM
32D-BCR-ABL Viable 96.5 94 47.1 4.6 
 Apoptotic 3.3* 5.8* 52.3* 95.3* 
 Necrotic 0.2 0.2 0.6 0.1 
32D-BCR-ABL-T315I Viable 96.6 90.8 89.9 27.2 
 Apoptotic 3.4* 9* 9.8* 72.7* 
 Necrotic 0.1 0.3 
Ba/F3-KIT-T670I Viable 96.8 97.7 96.9 91.6 
 Apoptotic 3.2* 2.3* 3.1* 8.4* 
 Necrotic 
Ba/F3-PDGFRα-T674M Viable 92.2 91 34.7 13.2 
 Apoptotic 7.8* 9* 65.2* 86.8* 
 Necrotic 0.1 
Ba/F3-PDGFRα-T674I Viable 87.3 61.9 15.2 5.8 
 Apoptotic 12.8* 38.1* 84.7* 94.1* 
 Necrotic 0.1 0.2 

Induction of apoptosis by HG-7-85-01 in BCR-ABL–, BCR-ABL-T315I–, KIT- T670I–, PDGFRα-T674M–, and PDGFRα-T674I–expressing cells after approximately 3 days of treatment.

*

Percentages of apoptotic cells for each cell line.

Close Modal

or Create an Account

Close Modal
Close Modal